ReviewAdvanced drug delivery reviews2026
Gas entrapping materials for damage control.
Review in Advanced drug delivery reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Controlled Delivery of Gasotransmitters for Cardiovascular Therapy: Molecular Mechanisms, Engineered Platforms, and Translational Perspectives.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gasotransmitters, including nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S), are small endogenously produced signaling molecules that regulate critical intra- and intercellular processes. These gases modulate ion channel activity, gene expression, redox balance, and mitochondrial bioenergetics, while influencing cardiovascular, immune, and nervous system functions. Despite their toxicity at high concentrations, controlled exogenous administration of gasotransmitters has enormous therapeutic potential in conditions such as cancer, cardiovascular disease, sepsis, trauma, and brain injury. A central challenge in translating these molecules into clinical use lies in achieving safe, targeted and tunable delivery. Traditional inhalation methods have evolved with advances in medicinal chemistry, and bioengineering, enabling formulations for oral, parenteral, and localized delivery that exploit the gases' ability to freely diffuse across membranes. This review summarizes current strategies for delivering NO, CO, and H₂S using hydrogels, foams, and solid formulations across skin and gut barrier sites. We discuss the mechanisms governing gasotransmitter activity, factors affecting tissue distribution and reactivity, and the potential clinical utility of these delivery approaches. By highlighting recent preclinical and clinical studies, we provide a framework for optimizing gasotransmitter administration, dosage, and specificity, emphasizing their translational relevance as therapeutic agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.